Every deal we've covered

Chinese technology group Midea has completed its acquisition of a majority stake in Esaote, the Genoa-based medical imaging company. Esaote will join Midea's Healthcare Division but keep operating as an independent global medical equipment company. Its R&D and production sites in Italy and the Netherlands remain in place.

Sopris Capital completed its purchase of AI imaging orchestration firm Blackford Analysis from Bayer and plans to combine it with portfolio company Azra AI.

ABL Texcell Diagnostics is acquiring IntegraGen's genomics and bioinformatics business and assets under an Évry Commercial Court ruling, as IntegraGen enters judicial liquidation.

Valerio Therapeutics completed its purchase of 100% of Etherna Immunotherapies NV, building an integrated targeted RNA platform.

Viatris agreed to buy Pacira BioSciences in a roughly $1.7B buyout. The deal brings in post-surgical pain drug Exparel and knee osteoarthritis therapy Zilretta, which together booked nearly $700M in 2025. Leerink expects the deal to be immediately accretive to revenue.

China's Midea Group has completed its acquisition of a controlling stake in Esaote, a Genoa-based medical imaging company known for ultrasound and dedicated MRI. Esaote will join Midea Healthcare, operate independently and stay under CEO Franco Fontana. Terms were not disclosed.

CardioOne joined forces with CardioSphere and welcomed Midwest Cardiovascular Institute to its independent cardiology network.

Pharma services platform Petauri acquired HEOR and market access consultancy Franklin Pharmaceutical Consulting.

Tevogen entered a non-binding, non-exclusive letter of intent to evaluate acquiring HRK Healthcare, targeting a close by year-end.

Eye-care VR diagnostics platform Carrot agreed to buy GreenMan Vision, maker of InSightVR, adding intraocular lens simulation for cataract surgery; terms were not disclosed.

Option Care Health agreed to be acquired by private equity firm CD&R and drug distributor McKesson for $32.05 per share in cash. The deal values the home and alternate-site infusion provider at about $5.8 billion. The offer is a roughly 37% premium to Option Care's October 5 closing price.

Medtronic set the final exchange ratio at 4.5939 MiniMed shares per Medtronic share in its exchange offer to split off MiniMed Group.

AmyriAD Therapeutics acquired Recognify and its cognition drug RL-007 in an all-share transaction.

Integrity Care Group acquired 15 NextCare urgent care clinics in Oklahoma, Missouri and Nebraska, reaching 100 locations.

SRX Global signed a definitive agreement to make CERo Therapeutics a wholly owned subsidiary via an SPV.

Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion. Pacira sells the non-opioid pain drugs EXPAREL and ZILRETTA and generated about $746 million in revenue and $177 million in adjusted EBITDA over the last twelve months.

Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health for $32.05 per share in a deal valued at about $5.8 billion. CD&R will hold majority ownership, while McKesson invests roughly $1.4 billion for about 49%, with a framework to potentially buy CD&R's stake later. Option Care shares jumped about 34%.

Harbor Health agreed to buy 27 Village Medical clinics in Greater Houston, bringing it to nearly 70 clinics; terms were not disclosed.

The Joint Corp. reacquired regional developer rights across Texas, including Dallas, Austin, San Antonio and Houston.

Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.